Minnesota-based Stimdia Medical has initiated the pivotal trial of its phrenic nerve stimulation technology to liberate patients from mechanical ventilation and save the health care system money.
Minute Insight: Stimdia Starts Trial Of Phrenic Nerve Stimulator For Patients On Ventilators
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
More from Minute Insights
• By
Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.
• By
The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.
• By
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
• By
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
More from Medtech Insight
• By
Abbott presented late-breaking data at the 2025 American College of Cardiology conference demonstrating that TriClip transcatheter edge-to-edge repair offers prolonged patient benefits compared to medical treatment alone after two years, which were not evident at one year.
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
• By
The Visby Medical Women’s Sexual Health Test is the first over-the-counter test cleared by the US Food and Drug Administration to detect chlamydia, gonorrhea and trichomoniasis. It delivers results in about 30 minutes.